Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label MAS825 trial in pediatric and adult Still's disease
NL-OMON60029Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MAS825 in adult-onset Still's disease (AOSD), sponsored by Novartis. Primary endpoint: Clinical response by composite endpoint. Started Jan 2026; status: active, not recruiting.
02
Drugs
MAS825
03
Conditions
adult-onset Still's disease (AOSD)
Beyond the preview
Go deeper on NL-OMON60029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60029.